Recursion Pharmaceuticals, Inc ((RXRX)) has held its Q3 earnings call. Read on for the main highlights of the call. Recursion Pharmaceuticals, Inc. recently held its earnings call, which conveyed an ...

Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. The recent earnings call for Recursion ...

Recursion Pharmaceuticals, Inc. recently held its earnings call, which conveyed an optimistic sentiment. The company is experiencing strong leadership transitions, maintaining a robust financial ...

Earnings call Recursion ended Q3 2025 with $785M in cash and no financing needs through 2027, aided by a 35% expense reduction and $40M in partnership inflows YTD. A $30M milestone from Roche ...

Earnings call Recursion ended the quarter with $533M in cash and reaffirmed its cash runway through Q4 2027. The company achieved a $7M milestone with Sanofi and expects over $100M in partnership ...

Company to host public (L)earnings call on August 5th at 8:00 am ET / 6:00 am MT / 1:00 pm BST Salt Lake City, UT, July 29, 2025 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX), a leading clinical stage ...

Achieved $30 million milestone from Roche and Genentech for delivering a whole-genome map of microglial immune cells—the second neuro map designed to accelerate treatments for a wide range of ...

Hello, and welcome, everybody, to Recursion's Q2 2025 Earnings Call. My name is Chris Gibson, and I'm the Co-Founder and CEO of Recursion. And I'm excited to share with you today some of the latest ...